Skip to main content
RENHE PHARMACY CO.,LTD logo

RENHE PHARMACY CO.,LTD — Investor Relations & Filings

Ticker · 000650 ISIN · CNE000000NF8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,739 across all filing types
Latest filing 2026-04-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000650

About RENHE PHARMACY CO.,LTD

https://www.renheyaoye.com

Renhe Pharmacy Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products and health-related commodities. The company maintains a diverse portfolio encompassing over-the-counter (OTC) medications, traditional Chinese medicines (TCM), health supplements, and personal care items. Its core product lines address various therapeutic areas, including respiratory health, digestive disorders, gynecology, and pediatrics. Renhe is recognized for its established brand equity, operating well-known labels such as Renhe, Youka, and Fuyan. The company integrates modern pharmaceutical technology with traditional medicinal practices to produce high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and an extensive marketing network, focusing on providing accessible healthcare products to a broad consumer base.

Recent filings

Filing Released Lang Actions
公司2025年度独立董事述职报告 (涂书田)
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Renhe Pharmaceutical Co., Ltd. for the year 2025. It includes descriptions of the director's duties, attendance at board and shareholder meetings, committee participation, communication with auditors, oversight of internal controls, and governance activities. The content focuses on the director's role in corporate governance, compliance with laws and regulations, and protection of shareholder interests. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. The document is a formal report on board/management activities and governance oversight by an independent director, fitting the category of Board/Management Information (MANG). The length and detail confirm it is a substantive report, not a brief announcement or certification.
2026-04-23 Chinese
公司董事、高级管理人员薪酬管理制度（2026年04月22日修订）
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, and mechanisms for determining and managing the compensation of the company's directors and senior executives. It references legal frameworks and company bylaws related to remuneration. There is no indication that this is a report or announcement of financial results, nor is it a proxy statement or voting result. The content is focused on remuneration policies and management, which aligns with the definition of Remuneration Information filings. The document length is under 5,000 characters but it is a substantive policy document, not a mere announcement or certification. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2026-04-23 Chinese
公司2025年度独立董事述职报告 (章美珍)
Management Reports Classification · 90% confidence The document is titled as an "Independent Director's Report" for the year 2025 by an independent director of the company. It details the director's attendance at board and committee meetings, supervision of financial reports, internal controls, communication with auditors, and oversight of governance and compliance matters. The content focuses on the director's duties, governance oversight, and compliance with regulations rather than presenting full financial statements or comprehensive financial performance data. The document length is 3843 characters, which is relatively short and consistent with a report or statement rather than a full annual or interim report. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement, earnings release, or other categories. The nature of the document fits best with a Management Report or Management Discussion and Analysis (MDA), as it provides management-level oversight and commentary on governance, financial reporting supervision, and company operations from the perspective of an independent director.
2026-04-23 Chinese
公司2025年度独立董事述职报告 (郭亚雄-届满离任)
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of a company, covering the director's duties, attendance at meetings, oversight activities, communication with auditors, and governance matters during the fiscal year 2025. It includes descriptions of the director's role in supervising internal controls, financial reporting, and board nominations. The document is titled as an "Independent Director's Work Report" for the year 2025. It is not a full annual report or financial statement, nor is it an announcement or certification. It focuses on board/management oversight and governance activities by an individual director. Therefore, it fits best under Board/Management Information (MANG), which covers announcements or reports related to changes or activities of the company's board or senior management, including independent directors' reports on their duties and performance.
2026-04-23 Chinese
公司2025年度独立董事述职报告 (伍红)
Governance Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2025" from Renhe Pharmaceutical Co., Ltd. It details the independent director's attendance at board and shareholder meetings, committee participation, communication with auditors, supervision of internal controls, and overall governance activities during the year 2025. The content focuses on the director's duties, oversight, and evaluation of company governance and financial reporting compliance. It does not contain financial statements or detailed financial data itself, nor is it an announcement of a report publication. This type of document is a report on the independent director's activities and governance oversight, which fits best under the category of Governance Information (CGR). The document length is under 5,000 characters, but it is a substantive report rather than a mere announcement, so it is not RPA or RNS. Therefore, the classification is CGR with high confidence.
2026-04-23 Chinese
公司关于董事、高级管理人员2026年度薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 annual remuneration scheme for the company's directors and senior management. It details the salary standards, payment methods, and principles for the remuneration of directors and senior executives. The document is a formal announcement of a management-related decision, specifically about compensation plans, and does not contain financial statements or audit information. It is not a full report like an annual report or interim report, nor is it a regulatory filing or proxy solicitation. The content fits best under Remuneration Information filings, which cover compensation details for top executives and directors.
2026-04-23 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.